Management of Low-Grade Gliomas.

3.3 years, n = 89, P = 0.0186), and there was also a positive trend toward survival improvement with PCV (10.5 vs. 7.2 years, P = 0.16). 39 The NOA-04 study similarly observed better PFS in PCV-treated patients compared with TMZ-treated patients with anaplastic oligodendroglioma with 1p/19q codeletion. 41 The French POLA cohort retrospective analysis of 355 anaplastic astrocytomas noted improved OS with RT/PCV compared with RT/TMZ, although RT/TMZ was better tolerated. 40 Four-year PFS and OS in RT/PCV were 70.8% and 84.3%, as opposed to 53.5% and 76.6% in RT/TMZ.

also in 6,774 other papers

It found that patients with anaplastic gliomas treated with PCV (n = 36) had a longer median time to progression (TTP) compared with BCNU (n = 36)—median TTP was 123 weeks, compared with 77 weeks 51 —although this did not reach statistical significance in the initial 1985 report.

also in 75,278 other papers